Dentists in Gunnison, UT Accepting Medicare
4 Dentists found. Showing 1 - 4
 Michael Hal Parsons, D.D.S. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 231 East 200 South, Gunnison, UT 84634 Phone: 435-528-3637 |
Dr. Shawn David Parkin, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 255 E 300 N, Gunnison, UT 84634 Phone: 435-528-6000 |
Dr. Kelly Mackay Frandsen, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 75 North 100 East, Box 386, Gunnison, UT 84634 Phone: 435-528-7316 |
Cutler Frandsen Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 75 N 100 E, Gunnison, UT 84634 Phone: 435-528-7316 |
News Archive
Mass. regulators reach rate hike accord with one more insurer
Massachusetts regulators cut a deal Monday with insurer Health New England to limit premium increases for individual policyholders and small businesses to 8.2 percent, down from the hikes ranging from 11.5 to 21.3 percent the firm requested earlier this year, The Boston Globe reports. "With the Health New England agreement, the Patrick administration has now reached accords with five of the six Massachusetts insurance carriers that were denied double-digit increases on April 1.
FDA approves Cubist Pharmaceuticals' sNDA for ENTEREG
Cubist Pharmaceuticals, Inc. today announced the approval of its supplemental new drug application (sNDA) by the U.S. Food and Drug Administration for ENTEREG (alvimopan).
FDA gives new safety information on proper use of Tussionex as a cough suppressant
The U.S. Food and Drug Administration issued an alert today on the safe and correct use of Tussionex Pennkinetic Extended-Release Suspension in response to numerous reports of adverse events - including death - associated with the misuse and inappropriate use of this potent cough medication.
Combination of exercise and S-nitrosoglutathione improves recovery from stroke
In a study published in the current issue of Restorative Neurology and Neuroscience scientists report that a therapy combining exercise with the neurovascular protective agent S-nitrosoglutathione (GSNO) improved recovery from stroke in a rat model. GSNO is a compound found naturally in the body and it has no known side effects or toxicity.
Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies
Pfizer Inc. announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.
› Verified 7 days ago
Dentists
Occupational Therapists
Pharmacists
Clinical Social Workers
Counselors